We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Marina Biotech Starts Cohort 2 of its Phase 1b START-FAP Clinical Trial of CEQ508

News   Jan 27, 2012

 
Marina Biotech Starts Cohort 2 of its Phase 1b START-FAP Clinical Trial of CEQ508
 
 
Advertisement
 

RELATED ARTICLES

Therapy for Nonalcoholic Fatty Liver Disease Shows Promise in Preclinical Tests

News

Scientists have discovered a new target and a new therapy for Nonalcoholic Fatty Liver Disease (NAFLD), that has shown promising results in preclinical mouse models.

READ MORE

Light-activated Nanoparticles Inhibit Tumor Growth

News

A unique nanoparticle to deliver a localized cancer treatment inhibits tumor growth in mice, according to new research conducted at Penn State University.

READ MORE

Controlled Human Infection Models for SARS-CoV-2 Vaccine Development

News

Infecting some volunteers with COVID-19 may provide valuable insights for future rounds of vaccine testing, but would require very strict controls, argues a group of infectious disease experts in the New England Journal of Medicine.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE